DESTINY Lung02 Final Analysis
DESTINY-Lung02: Final Analysis of Trastuzumab Deruxtecan in Previously Treated HER2-Mutated Metastatic NSCLC

Released: June 06, 2024

Expiration: June 05, 2025

Activity

Progress
1
Course Completed